These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27584663)

  • 1. The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer.
    Kleeff J; Costello E; Jackson R; Halloran C; Greenhalf W; Ghaneh P; Lamb RF; Lerch MM; Mayerle J; Palmer D; Cox T; Rawcliffe CL; Strobel O; Büchler MW; Neoptolemos JP
    Br J Cancer; 2016 Sep; 115(7):887-94. PubMed ID: 27584663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
    Ghaneh P; Kleeff J; Halloran CM; Raraty M; Jackson R; Melling J; Jones O; Palmer DH; Cox TF; Smith CJ; O'Reilly DA; Izbicki JR; Scarfe AG; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Padbury R; Shannon J; Dervenis C; Glimelius B; Deakin M; Anthoney A; Lerch MM; Mayerle J; Oláh A; Rawcliffe CL; Campbell F; Strobel O; Büchler MW; Neoptolemos JP;
    Ann Surg; 2019 Mar; 269(3):520-529. PubMed ID: 29068800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Surgical therapy of pancreatic cancer - 5 years survival].
    Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R
    Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
    Neoptolemos JP; Palmer DH; Ghaneh P; Psarelli EE; Valle JW; Halloran CM; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ma YT; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Hackert T; Jackson R; Büchler MW;
    Lancet; 2017 Mar; 389(10073):1011-1024. PubMed ID: 28129987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes of adjuvant chemotherapy in patients with stage I pancreatic cancer stratified by pathologic risk.
    Zou Y; Xie Y; Huang J; Liang Y; Chang S; Wang H; Wang Y; Gao C; Wang X; Zhao T; Yu J; Gao S; Hao J
    Surgery; 2024 Nov; 176(5):1466-1474. PubMed ID: 39191600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection.
    Cannon RM; LeGrand R; Chagpar RB; Ahmad SA; McClaine R; Kim HJ; Rupp C; Cho CS; Brinkman A; Weber S; Winslow ER; Kooby DA; Chu CK; Staley CA; Glenn I; Hawkins WG; Parikh AA; Merchant NB; McMasters KM; Martin RC; Callender GG; Scoggins CR
    HPB (Oxford); 2012 Apr; 14(4):228-35. PubMed ID: 22404260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medically managed hypercholesterolemia and insulin-dependent diabetes mellitus preoperatively predicts poor survival after surgery for pancreatic cancer.
    Chagpar RB; Martin RC; Ahmad SA; Kim HJ; Rupp C; Weber S; Ebelhar A; Gilbert J; Brinkman A; Winslow E; Cho CS; Kooby D; Chu CK; Staley CA; McMasters KM; Scoggins CR
    J Gastrointest Surg; 2011 Apr; 15(4):551-7. PubMed ID: 21327533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of familial pancreatic cancer on postoperative outcome in pancreatic cancer: relevance to adjuvant chemotherapy.
    Tezuka K; Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
    J Gastroenterol; 2021 Jan; 56(1):101-113. PubMed ID: 33094352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time trends in the treatment and prognosis of resectable pancreatic cancer in a large tertiary referral centre.
    Barugola G; Partelli S; Crippa S; Butturini G; Salvia R; Sartori N; Bassi C; Falconi M; Pederzoli P
    HPB (Oxford); 2013 Dec; 15(12):958-64. PubMed ID: 23490217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis.
    Mackay TM; Smits FJ; Roos D; Bonsing BA; Bosscha K; Busch OR; Creemers GJ; van Dam RM; van Eijck CHJ; Gerhards MF; de Groot JWB; Groot Koerkamp B; Haj Mohammad N; van der Harst E; de Hingh IHJT; Homs MYV; Kazemier G; Liem MSL; de Meijer VE; Molenaar IQ; Nieuwenhuijs VB; van Santvoort HC; van der Schelling GP; Stommel MWJ; Ten Tije AJ; de Vos-Geelen J; Wit F; Wilmink JW; van Laarhoven HWM; Besselink MG;
    HPB (Oxford); 2020 Feb; 22(2):233-240. PubMed ID: 31439478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of statin use on survival in patients undergoing resection for early-stage pancreatic cancer.
    Wu BU; Chang J; Jeon CY; Pandol SJ; Huang B; Ngor EW; Difronzo AL; Cooper RM
    Am J Gastroenterol; 2015 Aug; 110(8):1233-9. PubMed ID: 26195180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved survival after palliative resection of unsuspected stage IV pancreatic ductal adenocarcinoma.
    Kim Y; Kim SC; Song KB; Kim J; Kang DR; Lee JH; Park KM; Lee YJ
    HPB (Oxford); 2016 Apr; 18(4):325-31. PubMed ID: 27037201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base.
    Johnston WC; Hoen HM; Cassera MA; Newell PH; Hammill CW; Hansen PD; Wolf RF
    HPB (Oxford); 2016 Jan; 18(1):21-8. PubMed ID: 26776847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials.
    Butturini G; Stocken DD; Wente MN; Jeekel H; Klinkenbijl JH; Bakkevold KE; Takada T; Amano H; Dervenis C; Bassi C; Büchler MW; Neoptolemos JP;
    Arch Surg; 2008 Jan; 143(1):75-83; discussion 83. PubMed ID: 18209156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-operative dysglycemia is associated with decreased survival in patients with pancreatic neuroendocrine neoplasms.
    Sandini M; Strobel O; Hank T; Lewosinska M; Nießen A; Hackert T; Büchler MW; Schimmack S
    Surgery; 2020 Mar; 167(3):575-580. PubMed ID: 31889543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
    Xie H; Lin J; Thomas DG; Jiang W; Liu X
    Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy.
    Fischer R; Breidert M; Keck T; Makowiec F; Lohrmann C; Harder J
    Saudi J Gastroenterol; 2012; 18(2):118-21. PubMed ID: 22421717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma.
    Lewis R; Drebin JA; Callery MP; Fraker D; Kent TS; Gates J; Vollmer CM
    HPB (Oxford); 2013 Jan; 15(1):49-60. PubMed ID: 23216779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival.
    John BJ; Naik P; Ironside A; Davidson BR; Fusai G; Gillmore R; Watkins J; Rahman SH
    HPB (Oxford); 2013 Sep; 15(9):674-80. PubMed ID: 23458477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.